Edition:
United Kingdom

Epizyme Inc (EPZM.OQ)

EPZM.OQ on NASDAQ Stock Exchange Global Select Market

12.70USD
15 Dec 2017
Change (% chg)

-- (--)
Prev Close
$12.70
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
160,922
52-wk High
$20.40
52-wk Low
$9.35

Latest Key Developments (Source: Significant Developments)

Epizyme says ‍no revenue recognized in Q3 of 2017 compared to $6.6 mln for Q3 of 2016​
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Epizyme Inc :Epizyme reports third quarter 2017 operating results and company updates.Epizyme Inc - ‍no revenue recognized in q3 of 2017, compared to $6.6 million for q3 of 2016​.Epizyme Inc - ‍research and development (research and development) expenses were $28.7 million for q3 of 2017, compared to $23.9 million​.Epizyme Inc - ‍existing cash, cash equivalents and marketable securities as of sept 30 will be sufficient to fund planned operations into at least q3 2019​.  Full Article

Epizyme reported Q2 EPS ($0.49)
Monday, 8 Aug 2016 

Epizyme Inc : Epizyme announces second quarter 2016 financial results and progress against corporate objectives . Qtrly loss per share $0.49 . Q2 earnings per share view $-0.52 -- Thomson Reuters I/B/E/S .Believes cash, cash equivalents as of June 30, 2016 will be sufficient to fund company's planned operations into at least Q2 of 2018.  Full Article

Epizyme to work with Lymphoma Study Association
Monday, 9 May 2016 

Epizyme Inc : Epizyme announces collaboration with Lymphoma Study Association to evaluate combination of Tazemetostat with R-Chop in front-line Non-Hodgkin Lymphoma . Phase 1B/2 trial will be jointly conducted with Lymphoma Academic Research Organisation (LYSARC), operational arm of LYSA . Company has announced plans to initiate additional clinical evaluations of Tazemetostat in 2016 . Open-Label, clinical study will be sponsored by LYSARC and conducted at multiple sites in france .Epizyme and LYSARC jointly designed study, which is expected to begin enrolling patients mid-year.  Full Article

Epizyme Announces Proposed Public Offering of Common Stock
Tuesday, 5 Jan 2016 

Epizyme Inc :Announces proposed public offering of common stock.Says intends to offer and sell up to $120,000,000 of shares of its common stock in an underwritten public offering.Says intends to grant the underwriters a 30-day option to purchase up to an additional $18 million of shares of its common stock.Says intends to use the net proceeds to fund the global development costs of tazemetostat, epizyme's novel oral ezh2 inhibitor.  Full Article